The FDA would discourage a combined filing, IMO; if GILD persisted with such an application, the FDA might restrict the label to gentotypes-1 and -2. However, as noted in #msg-84287176, I don’t GILD will put itself in this position.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.